Exploratory research on novel therapeutic seeds for dementia targeting inhibition of neurogenesis by glycosylated proteins

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K06637
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47050:Environmental and natural pharmaceutical resources-related
• Research Institution: Kindai University
• Principal Investigator: Nakashima Souichi 近畿大学, 薬学総合研究所, 研究員 (50724639)
• Co-Investigator(Kenkyū-buntansha): 中村 誠宏 京都薬科大学, 薬学部, 准教授 (20411035)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 神経新生 / 認知症治療薬 / 標的タンパク質 / 糖化タンパク質 / オオバゲッキツ / オトメアゼナ

Outline of Final Research Achievements

In the search for seed compounds for dementia drugs based on a new mechanism, we found several promising compounds, including carbazole-type alkaloids, from five herbal medicines. Even for herbal ingredients that were not expected to act by the mechanism described above, we found that phenylpropanoid glycosides and other compounds inhibited cognitive dysfunction based on the Aβ oligomer hypothesis. We also demonstrated the usefulness of the therapeutic drug seed discovery method based on the search for target-binding substances, which was the main method used in conducting this study.

Free Research Field

生薬学、天然物化学、認知症治療薬

Academic Significance and Societal Importance of the Research Achievements

本研究では新規メカニズムによる認知症治療薬シードを数点見出したこと以外に、ターゲットに直接結合する成分の分析手法や、予定外であった作用による有効成分を見出すことが出来た。これらのことから本研究成果は、新たな治療薬候補を開発するにとどまらず、新たな視点による認知症治療方法の開発の一助となることが期待できる。また本研究で確立した検出手法についても、今後の類似研究への応用が期待できる。